Episode 2: Pfizer Sticks It to U.S. Treasury
(Bloomberg) -- In this episode, Alex and Global MaA Managing Editor McCracken discuss the largest deal of the year and the biggest health care deal ever, Pfizer Inc. and Allergan Plc's $160 billion merger. They ponder whether the deal, constructed so that Pfizer will pay lower taxes by domiciling in Ireland, opens the door for more so-called inversions just as the U.S. Treasury tries to crack down on them. Frank Aquila, a partner at Sullivan a Cromwell, joins Alex and Jeff to compare MaA in the 1980s with the present day, crediting companies and their advisers for doing smarter deals now, while regretting one particular merger that never got done.
